Clinical Trial Update: A Study to Evaluate the Safety and Immunogenicity of Ad5-105K in Adults Aged 18 to 49 Years [Phase 1]

View source ↗

Summary

This document provides an update on a Phase 1 trial evaluating the safety and immunogenicity of the Ad5-105K candidate in adults aged 18–49. The study targets t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• Ad5-105K

Snippet

Sponsor: CanSino Biologics Inc. | Conditions: Tuberculosis | Phase 1 | Status: RECRUITING